The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

Stocks•7 May 2026•

1 min read

Mixed Q1 Results for Aldeyra and ITW as Losses Narrow and Operating Revenue Grows

Key Facts

1Aldeyra Therapeutics reported a net loss of $3.5 million, an improvement from a $9.9 million loss in the previous year.

2Illinois Tool Works operating revenue increased to $4,016 million with diluted EPS growing 11.8%.

3Aldeyra maintains cash equivalents sufficient to cover obligations into the second half of 2028.

Quarterly financial filings for Aldeyra Therapeutics and Illinois Tool Works (ITW) revealed a mixed but generally positive performance for the period ended March 31. Aldeyra Therapeutics reported a significantly narrowed net loss of $3.5 million, down from $9.9 million in the prior year, while maintaining a cash runway that extends into the second half of 2028. Meanwhile, industrial giant ITW saw its operating revenue climb to $4,016 million, bolstered by an 11.8% growth in diluted earnings per share (EPS). The 10-Q filings highlight Aldeyra's improved financial stability and ITW's consistent operational growth and share repurchase activity. These results suggest a resilient outlook for both the healthcare and industrial sectors amid standard regulatory reporting.